Forecasting Covid-19 Mortality in Ecuador

Abstract

In this study, the ANN approach was applied to analyze COVID-19 deaths in Ecuador. The employed data covers the period 1 January 2020 to 20 April 2021 and the out-of-sample period ranges over the period21 April to 31 August 2021. The residuals and forecast evaluation criteria (Error, MSE and MAE) of the applied model indicate that the model is quite stable. The results of the study indicate that daily COVID-19 deaths in Ecuador are likely to be close to 40 deaths per day over the out-of-sample period. Therefore there is need for the government of Ecuador to ensure adherence to safety guidelines while continuing to create awareness about the COVID-19 pandemic and scale up COVID-19 vaccination. 

Country : Zimbabwe

1 Dr. Smartson. P. NYONI2 Mr. Thabani NYONI3 Mr. Tatenda. A. CHIHOHO

  1. ZICHIRe Project, University of Zimbabwe, Harare, Zimbabwe
  2. SAGIT Innovation Center, Harare, Zimbabwe
  3. Independent Health Economist, Harare, Zimbabwe

IRJIET, Volume 5, Issue 6, June 2021 pp. 157-162

doi.org/10.47001/IRJIET/2021.506030

References

  1. K. Karunathilake (2020). Positive and negative impacts of COVID‑19, an analysis with special reference to challenges on the supply chain in South Asian countries, Journal of Social and Economic Development https://doi.org/10.1007/s40847-020-00107-z, pp 1-14.
  2. Eric Toner (2021). Potential Solutions to the COVID-19 Oxygen Crisis in the United States , Johns Hopkins Center for Health Security, centerforhealthsecurity.org, pp 1-3.
  3. CDC (2020). The Novel Coronavirus Pneumonia Emergency Response Epidemiology Team, The epidemiological characteristics of an outbreak of 2019 novel coronavirus diseases (COVID-19) in China. China CDC Weekly 2, 113–122
  4. Read et al (2020). Novel coronavirus 2019-nCoV: Earlyestimationofepidemiologicalparametersandepidemicpredictions. medRxiv:10.1101/2020.01.23.20018549
  5. Tang. B et al (2020).  An updated estimation of the risk of transmission of the novel coronavirus (2019-nCoV). Infectious Disease Modelling 5, 248–255.
  6. Tang. B et al (2020). Estimation of the transmission risk of the 2019-nCoV and its implication for public health interventions. J. Clinical Med. 9, 462.
  7. Wang D et al (2020).  Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus–infected pneumonia in Wuhan, China. JAMA 323, 1061–1069.
  8. Wang H et al (2020). Phase-adjusted estimation of the number of coronavirus disease 2019 cases in Wuhan, China. Cell Discovery 6, 76.
  9. Wang. W et al (2020). Updated understanding of the outbreak of 2019 novel coronavirus (2019-nCoV) in Wuhan, China. J. Med. Virology 92, 441–447.
  10. ILO (2020). ILO Monitor: COVID-19 and the world of work. Second edition, pp 1-11.